Ubs Group Ag Outlook Therapeutics, Inc. Transaction History

Ubs Group Ag

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.22 - $0.66 $27,678 - $83,036	125,813 New	125,813 $49,000
Q2 2023 Aug 11, 2023	SELL	$1.02 - $1.89 $4,162 - $7,713	-4,081 Reduced 44.77%	5,035 $8,000
Q1 2023 May 12, 2023	SELL	$1.0 - $1.35 $9,065 - $12,237	-9,065 Reduced 49.86%	9,116 $9,000
Q4 2022 Feb 08, 2023	BUY	$0.87 - $1.33 $15,817 - $24,180	18,181 New	18,181 $19,000
Q2 2022 Aug 10, 2022	SELL	$0.91 - $2.01 $1,185 - $2,619	-1,303 Reduced 47.54%	1,438 $1,000

Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $35,560 - $59,170	-29,148 Reduced 91.4%	2,741 $5,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $40,499 - $71,112	31,889 New	31,889 $43,000
Q3 2021 Nov 15, 2021	SELL	$2.12 - $2.76 $10,752 - $13,998	-5,072 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$1.78 - $2.76 $3,164 - $4,907	-1,778 Reduced 25.96%	5,072 $13,000
Q1 2021 May 12, 2021	SELL	$0.94 - $3.31 $2,020 - $7,116	-2,150 Reduced 23.89%	6,850 $15,000
Q4 2020 Feb 11, 2021	BUY	$0.7 - $1.58 $1,060 - $2,393	1,515 Added 20.24%	9,000 $12,000
Q3 2020 Nov 12, 2020	SELL	$0.61 - $1.6 $924 - $2,424	-1,515 Reduced 16.83%	7,485 $5,000
Q2 2020 Jul 31, 2020	BUY	$0.56 - $1.41 $4,935 - $12,426	8,813 Added 4712.83%	9,000 $12,000
Q4 2019 Feb 14, 2020	SELL	$0.53 - $1.59 $1,876 - $5,628	-3,540 Reduced 94.98%	187 $0
Q3 2019 Nov 14, 2019	SELL	$1.32 - $2.63 $2,539 - $5,060	-1,924 Reduced 34.05%	3,727 $5,000
Q2 2019 Aug 14, 2019	BUY	$0.91 - $7.68 $4,972 - $41,963	5,464 Added 2921.93%	5,651 $11,000
Q1 2019 May 14, 2019	BUY	$4.26 - $10.56 $796 - $1,974	187 New	187 $1,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.66B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.